Advanced search
Publication Cover
Expert Review of Vaccines Volume 6, 2007 - Issue 5
Submit an article Journal homepage
1,158
Views
215
CrossRef citations to date
0
Altmetric
Review

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection

Derek T O’HaganHead of Vaccine Delivery Research, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy. [email protected]
Pages 699-710 | Published online: 09 Jan 2014

Citations (215)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (28)

Dylan A. Hendy, Alex Haven, Eric M. Bachelder & Kristy M. Ainslie. (2023) Preclinical developments in the delivery of protein antigens for vaccination. Expert Opinion on Drug Delivery 20:3, pages 367-384.
Read now
Sharon S. Frey, Eve Versage, Esther Van Twuijver & Matthew Hohenboken. (2023) Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults. Human Vaccines & Immunotherapeutics 19:1.
Read now
Kimia Kardani, Seyed Mehdi Sadat, Mona Kardani & Azam Bolhassani. (2021) The next generation of HCV vaccines: a focus on novel adjuvant development. Expert Review of Vaccines 20:7, pages 839-855.
Read now
Aurelio Cruz-Valdez, Gabriel Valdez-Zapata, Sanjay S. Patel, Flavia V. Castelli, Marcia G. Garcia, Wim T. Jansen, Ashwani Kumar Arora & Esther Heijnen. (2018) MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico. Human Vaccines & Immunotherapeutics 14:2, pages 386-395.
Read now
Emilia Nunzi, Anna Maria Iorio & Barbara Camilloni. (2017) A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60–85 years old) and very elderly (>85 years old) institutionalized subjects. Human Vaccines & Immunotherapeutics 13:11, pages 2659-2668.
Read now
Varun K. Phadke & Saad B. Omer. (2016) Maternal vaccination for the prevention of influenza: current status and hopes for the future. Expert Review of Vaccines 15:10, pages 1255-1280.
Read now
Barbara Camilloni, Michela Basileo, Stefano Valente, Emilia Nunzi & Anna Maria Iorio. (2015) Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Human Vaccines & Immunotherapeutics 11:3, pages 553-563.
Read now
Markus Knuf, Geert Leroux-Roels, Hans Rümke, Luis Rivera, Paola Pedotti, Ashwani Kumar Arora, Maria Lattanzi, Dorothee Kieninger & Giovanni Della Cioppa. (2015) Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children . Human Vaccines & Immunotherapeutics 11:2, pages 358-376.
Read now
Fazren Azmi, Abdullah Al Hadi Ahmad Fuaad, Mariusz Skwarczynski & Istvan Toth. (2014) Recent progress in adjuvant discovery for peptide-based subunit vaccines. Human Vaccines & Immunotherapeutics 10:3, pages 778-796.
Read now
David W. Scheifele, Shelly A. McNeil, Brian J. Ward, Marc Dionne, Curtis Cooper, Brenda Coleman, Mark Loeb, Ethan Rubinstein, Janet McElhaney, Todd Hatchette, Yan Li, Emanuele Montomoli, Amy Schneeberg, Julie A. Bettinger, Scott A. Halperin & PHAC/CIHR Influenza Research Network. (2013) Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Human Vaccines & Immunotherapeutics 9:11, pages 2460-2473.
Read now
Orli Even-Or, Sarit Samira, Ronald Ellis, Eli Kedar & Yechezkel Barenholz. (2013) Adjuvanted influenza vaccines. Expert Review of Vaccines 12:9, pages 1095-1108.
Read now
Larry R. Smith, Walter Wodal, Brian A. Crowe, Astrid Kerschbaum, Peter Bruehl, Michael G. Schwendinger, Helga Savidis-Dacho, Sean M. Sullivan, Mark Shlapobersky, Jukka Hartikka, Alain Rolland, P. Noel Barrett & Otfried Kistner. (2013) Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Human Vaccines & Immunotherapeutics 9:6, pages 1333-1345.
Read now
Derek T O’Hagan, Gary S Ott, Gary Van Nest, Rino Rappuoli & Giuseppe Del Giudice. (2013) The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Review of Vaccines 12:1, pages 13-30.
Read now
Ali Rowhani-Rahbar, Nicola P Klein & Roger Baxter. (2012) Assessing the safety of influenza vaccination in specific populations: children and the elderly. Expert Review of Vaccines 11:8, pages 973-984.
Read now
Timo Vesikari, Aino Forstén, Astrid Borkowski, Nikolaos Gaitatzis, Angelika Banzhoff & Ralf Clemens. (2012) Homologous and heterologous antibody responses to a one-year booster dose of an MF59®: Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Human Vaccines & Immunotherapeutics 8:7, pages 921-928.
Read now
Manmohan Singh, Jina Kazzaz, Mildred Ugozzoli, Barbara Baudner, Mariagrazia Pizza, Marzia Giuliani, Lynn D. Hawkins, Gillis Otten & Derek T. O’Hagan. (2012) MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Human Vaccines & Immunotherapeutics 8:4, pages 486-490.
Read now
Philip Dormitzer, Theodore Tsai & Giuseppe Del Giudice. (2012) New technologies for influenza vaccines. Human Vaccines & Immunotherapeutics 8:1, pages 45-58.
Read now
Siddhartha Jain, Derek T O’Hagan & Manmohan Singh. (2011) The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Review of Vaccines 10:12, pages 1731-1742.
Read now
Joan Puig-Barberà, Silvia Pérez-Vilar & Javier Díez-Domingo. (2011) MF59™-adjuvanted seasonal influenza vaccine in young children. Expert Review of Vaccines 10:11, pages 1519-1528.
Read now
Nicola Principi, Susanna Esposito & Paola Marchisio. (2011) Present and future of influenza prevention in pediatrics. Expert Opinion on Biological Therapy 11:5, pages 641-653.
Read now
Derek T O’Hagan, Rino Rappuoli, Ennio De Gregorio, Theodore Tsai & Giuseppe Del Giudice. (2011) MF59 adjuvant: the best insurance against influenza strain diversity. Expert Review of Vaccines 10:4, pages 447-462.
Read now
Antu K Dey & Indresh K Srivastava. (2011) Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Review of Vaccines 10:2, pages 227-251.
Read now
Paolo Durando, Giancarlo Icardi & Filippo Ansaldi. (2010) MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opinion on Biological Therapy 10:4, pages 639-651.
Read now
Rogier Bodewes, Guus F Rimmelzwaan & Albert DME Osterhaus. (2010) Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Review of Vaccines 9:1, pages 59-72.
Read now
Frederick R Vogel, Catherine Caillet, Inca C Kusters & Jean Haensler. (2009) Emulsion-based adjuvants for influenza vaccines. Expert Review of Vaccines 8:4, pages 483-492.
Read now
Isabel Leroux-Roels & Geert Leroux-Roels. (2009) Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Review of Vaccines 8:4, pages 401-423.
Read now
Ali M Harandi, Gwyn Davies & Ole F Olesen. (2009) Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Review of Vaccines 8:3, pages 293-298.
Read now
Sue D Xiang, Karen Scalzo-Inguanti, Gabriela Minigo, Anthony Park, Charles L Hardy & Magdalena Plebanski. (2008) Promising particle-based vaccines in cancer therapy. Expert Review of Vaccines 7:7, pages 1103-1119.
Read now

Articles from other publishers (187)

Dylan A. Hendy, Erik S. Pena, Luis Ontiveros‐Padilla, Timothy A. Dixon, Denzel D. Middleton, Grace L. Williamson, Nicole Rose Lukesh, Sean R. Simpson, Rebeca T. Stiepel, Md Jahirul Islam, Michael A. Carlock, Ted M. Ross, Eric M. Bachelder & Kristy M. Ainslie. (2023) Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations. Bioengineering & Translational Medicine.
Crossref
Federica Compostella, Laura Morelli & Luigi Lay. 2023. Carbohydrate‐Based Therapeutics. Carbohydrate‐Based Therapeutics 1 56 .
Priyanka, Mai Abdel Haleem Abusalah, Hitesh Chopra, Abhilasha Sharma, Suhad Asad Mustafa, Om Prakash Choudhary, Manish Sharma, Manish Dhawan, Rajiv Khosla, Aanchal Loshali, Ankush Sundriyal & Jyoti Saini. (2023) Nanovaccines: A game changing approach in the fight against infectious diseases. Biomedicine & Pharmacotherapy 167, pages 115597.
Crossref
Kun Chen, Ming Jiang, Jin Liu, Deli Huang & Yuhe R. Yang. (2023) DNA nanostructures as biomolecular scaffolds for antigen display . WIREs Nanomedicine and Nanobiotechnology.
Crossref
Dmitri Kazmin, Elizabeth A. Clutterbuck, Giorgio Napolitani, Amanda L. Wilkins, Andrea Tarlton, Amber J. Thompson, Emmanuele Montomoli, Guilia Lapini, Smiti Bihari, Rachel White, Claire Jones, Matthew D. Snape, Ushma Galal, Ly-Mee Yu, Rino Rappuoli, Giuseppe Del Giudice, Andrew J. Pollard & Bali Pulendran. (2023) Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children. npj Vaccines 8:1.
Crossref
Senyu Xu, Huixin Duan, Yaling An, Xiyue Jin, Minrun Duan, Patrice M. Dubois, Yan Huang, Kun Xu, Heng Du, Harry Kleanthous, Lianpan Dai & George F. Gao. (2023) Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™. Vaccine 41:17, pages 2793-2803.
Crossref
Dandan Peng, Tingmei Zhao, Weiqi Hong, Minyang Fu, Cai He, Li Chen, Wenyan Ren, Hong Lei, Jingyun Yang, Aqu Alu, Yanghong Ni, Jian Liu, Jiong Li, Wei Wang, Guobo Shen, Zhiwei Zhao, Li Yang, Jinliang Yang, Zhenling Wang, Yoshimasa Tanaka, Guangwen Lu, Xiangrong Song & Xiawei Wei. (2023) Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine. MedComm 4:2.
Crossref
Jesse Bodle, Kirsten Vandenberg, Karen Laurie, Ian G. Barr, Ying Zhang & Steven Rockman. (2023) An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines. Frontiers in Immunology 14.
Crossref
Allegra Peletta, Céline Lemoine, Thomas Courant, Nicolas Collin & Gerrit Borchard. (2023) Meeting vaccine formulation challenges in an emergency setting: Towards the development of accessible vaccines. Pharmacological Research 189, pages 106699.
Crossref
Jinxing Song, Mengxiang Wang, Yongkun Du, Bo Wan, Angke Zhang, Yuhang Zhang, Guoqing Zhuang, Pengchao Ji, Yanan Wu & Gaiping Zhang. (2023) Identification of a linear B-cell epitope on the African swine fever virus CD2v protein. International Journal of Biological Macromolecules 232, pages 123264.
Crossref
Soren Nooraei, Alireza Sarkar Lotfabadi, Milad Akbarzadehmoallemkolaei & Nima Rezaei. (2023) Immunogenicity of Different Types of Adjuvants and Nano-Adjuvants in Veterinary Vaccines: A Comprehensive Review. Vaccines 11:2, pages 453.
Crossref
Jesús Ruiz-Aragón & Sergio Márquez-Peláez. (2023) An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain. Vaccines 11:2, pages 427.
Crossref
Simon de Lusignan, Mansoor Ashraf, Filipa Ferreira, Manasa Tripathy, Ivelina Yonova, Imran Rafi, George Kassianos & Mark Joy. (2023) Impact of General Practitioner Education on Acceptance of an Adjuvanted Seasonal Influenza Vaccine among Older Adults in England. Behavioral Sciences 13:2, pages 130.
Crossref
Kwang Hyun Ko, Seung Bin Cha, Seung-Hwan Lee, Hyun Shik Bae, Chul Soo Ham, Min-Gyu Lee, Dong-Ho Kim & Seung Hyun Han. (2023) A novel defined TLR3 agonist as an effective vaccine adjuvant. Frontiers in Immunology 14.
Crossref
Rajashri Bezbaruah, Vivek P. Chavda, Lawandashisha Nongrang, Shahnaz Alom, Kangkan Deka, Tutumoni Kalita, Farak Ali, Bedanta Bhattacharjee & Lalitkumar Vora. (2022) Nanoparticle-Based Delivery Systems for Vaccines. Vaccines 10:11, pages 1946.
Crossref
Rokon Uz Zaman, Rikhav P. Gala, Amit Bansal, Priyal Bagwe & Martin J. D'Souza. (2022) Preclinical evaluation of a microparticle-based transdermal vaccine patch against metastatic breast cancer. International Journal of Pharmaceutics 627, pages 122249.
Crossref
Sachin S. Shivatare, Vidya S. Shivatare & Chi-Huey Wong. (2022) Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments. Chemical Reviews 122:20, pages 15603-15671.
Crossref
Fumi Sato-Kaneko, Shiyin Yao, Fitzgerald S. Lao, Yukiya Sako, Jasmine Jin, Nikunj M. Shukla, Howard B. Cottam, Michael Chan, Masiel M. Belsuzarri, Dennis A. Carson & Tomoko Hayashi. (2022) A Dual Adjuvant System for Intranasal Boosting of Local and Systemic Immunity for Influenza Vaccination. Vaccines 10:10, pages 1694.
Crossref
Feixia Gao, Xueying Liu, Yudong Dang, Peng Duan, Wenting Xu, Xin Zhang, Shilei Wang, Jian Luo & Xiuling Li. (2022) AddaVax-Adjuvanted H5N8 Inactivated Vaccine Induces Robust Humoral Immune Response against Different Clades of H5 Viruses. Vaccines 10:10, pages 1683.
Crossref
Sally A. Helmy, Rasha M. El-Morsi, Soha A.M. Helmy & Soha M. El-Masry. (2022) Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. Journal of Drug Delivery Science and Technology 76, pages 103762.
Crossref
Charlotte Switzer, Chris P. Verschoor, Eleanor Pullenayegum, Pardeep Singh & Mark Loeb. (2022) Adjuvant-attenuated symptom severity of influenza infections in vaccinated children. Infectious Medicine 1:3, pages 163-170.
Crossref
Woojong Lee & M. Suresh. (2022) Vaccine adjuvants to engage the cross-presentation pathway. Frontiers in Immunology 13.
Crossref
Matthew D. Gallovic, Robert D. Junkins, Adam M. Sandor, Erik S. Pena, Christopher J. Sample, Ariel K. Mason, Leslee C. Arwood, Rebecca A. Sahm, Eric M. Bachelder, Kristy M. Ainslie, Gregory D. Sempowski & Jenny P.-Y. Ting. (2022) STING agonist-containing microparticles improve seasonal influenza vaccine efficacy and durability in ferrets over standard adjuvant. Journal of Controlled Release 347, pages 356-368.
Crossref
Amjad Islam Aqib, Tean Zaheer, Muhammad Usman, Muhammad Arslan & Khazeena Atta. 2022. Nanovaccinology as Targeted Therapeutics. Nanovaccinology as Targeted Therapeutics 267 282 .
Robert A. Mitchell, Rita Altszuler, Sandra Gonzalez, Roshawn Johnson, Ute Frevert & Elizabeth Nardin. (2022) Innate Immune Responses and P. falciparum CS Repeat-Specific Neutralizing Antibodies Following Vaccination by Skin Scarification. Frontiers in Immunology 13.
Crossref
Jenny E. Hernandez-Davies, Emmanuel P. Dollinger, Egest J. Pone, Jiin Felgner, Li Liang, Shirin Strohmeier, Sharon Jan, Tyler J. Albin, Aarti Jain, Rie Nakajima, Algimantas Jasinskas, Florian Krammer, Aaron Esser-Kahn, Philip L. Felgner, Qing Nie & D. Huw Davies. (2022) Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants. Scientific Reports 12:1.
Crossref
Wade T. Johnson, Nicholas C. Dorn, Dora A. Ogbonna, Nunzio Bottini & Nisarg J. Shah. (2021) Lipid‐based regulators of immunity. Bioengineering & Translational Medicine 7:2.
Crossref
Chinekwu Sherridan Nwagwu, Chinenye Nnenna Ugwu, John Dike Nwabueze Ogbonna, Adaeze Linda Onugwu, Chinazom Precious Agbo, Adaeze Chidiebere Echezona, Ezinwanne Nneoma Ezeibe, Samuel Uzondu, Frankline Chimaobi Kenechukwu, Paul Achile Akpa, Mumuni Audu Momoh, Petra Obioma Nnamani, Clemence Tarirai, Kenneth Chibuzor Ofokansi & Anthony Amaechi Attama. 2022. Covid-19: Biomedical Perspectives. Covid-19: Biomedical Perspectives 151 188 .
Rushit N. Lodaya, Sonia Gregory, Mansoor M. Amiji & Derek T. O'Hagan. 2022. Practical Aspects of Vaccine Development. Practical Aspects of Vaccine Development 9 25 .
Zrinka Matić & Maja Šantak. (2021) Current view on novel vaccine technologies to combat human infectious diseases. Applied Microbiology and Biotechnology 106:1, pages 25-56.
Crossref
Ashish Singla & Sreedevi Upadhyayula. 2022. Handbook of Smart Materials, Technologies, and Devices. Handbook of Smart Materials, Technologies, and Devices 729 777 .
Mahmoud Ebrahimi, Nafiseh Farhadian, Ali Reza Amiri, Fatemeh Hataminia, Sara Saffar Soflaei & Mohammad Karimi. (2021) Evaluating the efficacy of extracted squalene from seed oil in the form of microemulsion for the treatment of COVID‐19: A clinical study. Journal of Medical Virology 94:1, pages 119-130.
Crossref
Evrim DÖNMEZ, Hafize Tuğba YÜKSEL DOLGUN & Şükrü KIRKAN. (2021) Nanopartiküler AşılarNanoparticular Vaccines. Journal of Anatolian Environmental and Animal Sciences 6:4, pages 578-584.
Crossref
Maria Tsakiri, Nikolaos Naziris & Costas Demetzos. (2021) Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. International Journal of Pharmaceutics 610, pages 121212.
Crossref
Lena Ernst, Eudald Casals, Paola Italiani, Diana Boraschi & Victor Puntes. (2021) The Interactions between Nanoparticles and the Innate Immune System from a Nanotechnologist Perspective. Nanomaterials 11:11, pages 2991.
Crossref
Pornthep Chanthavanich, Eve Versage, Esther Van Twuijver & Matthew Hohenboken. (2021) Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects. Vaccine 39:47, pages 6930-6935.
Crossref
Hossam H. Tayeb, Raed Felimban, Sarah Almaghrabi & Nojod Hasaballah. (2021) Nanoemulsions: Formulation, characterization, biological fate, and potential role against COVID-19 and other viral outbreaks. Colloid and Interface Science Communications 45, pages 100533.
Crossref
Julia Ritzau-Jost & Andreas Hutloff. (2021) T Cell/B Cell Interactions in the Establishment of Protective Immunity. Vaccines 9:10, pages 1074.
Crossref
Jenny E. Hernandez-Davies, Jiin Felgner, Shirin Strohmeier, Egest James Pone, Aarti Jain, Sharon Jan, Rie Nakajima, Algimantas Jasinskas, Erwin Strahsburger, Florian Krammer, Philip L. Felgner & D. Huw Davies. (2021) Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components. Frontiers in Immunology 12.
Crossref
Nadine G. Rouphael, Lilin Lai, Sonia Tandon, Michele Paine McCullough, Yunchuan Kong, Sarah Kabbani, Muktha S. Natrajan, Yongxian Xu, Yerun Zhu, Dongli Wang, Jesse O’Shea, Amy Sherman, Tianwei Yu, Sebastien Henry, Devin McAllister, Daniel Stadlbauer, Surender Khurana, Hana Golding, Florian Krammer, Mark J. Mulligan & Mark R. Prausnitz. (2021) Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. npj Vaccines 6:1.
Crossref
Daniel Ellis, Natalie Brunette, Katharine H. D. Crawford, Alexandra C. Walls, Minh N. Pham, Chengbo Chen, Karla-Luise Herpoldt, Brooke Fiala, Michael Murphy, Deleah Pettie, John C. Kraft, Keara D. Malone, Mary Jane Navarro, Cassandra Ogohara, Elizabeth Kepl, Rashmi Ravichandran, Claire Sydeman, Maggie Ahlrichs, Max Johnson, Alyssa Blackstone, Lauren Carter, Tyler N. Starr, Allison J. Greaney, Kelly K. Lee, David Veesler, Jesse D. Bloom & Neil P. King. (2021) Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Frontiers in Immunology 12.
Crossref
Adam M. Sandor, Michael S. Sturdivant & Jenny P. Y. Ting. (2021) Influenza Virus and SARS-CoV-2 Vaccines. The Journal of Immunology 206:11, pages 2509-2520.
Crossref
Saed Abbasi & Satoshi Uchida. (2021) Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines. Pharmaceutics 13:5, pages 644.
Crossref
Maryam Behzadi, Bahareh Vakili, Alireza Ebrahiminezhad & Navid Nezafat. (2021) Iron nanoparticles as novel vaccine adjuvants. European Journal of Pharmaceutical Sciences 159, pages 105718.
Crossref
Nilgun Yakubogullari, Furkan Ozan Coven, Nusin Cebi, Fethiye Coven, Nejdet Coven, Rukan Genc, Erdal Bedir & Ayse Nalbantsoy. (2021) Evaluation of adjuvant activity of Astragaloside VII and its combination with different immunostimulating agents in Newcastle Disease vaccine. Biologicals 70, pages 28-37.
Crossref
Glenda E. Gray, Linda-Gail BekkerFatima LaherMookho MalahlehaMary AllenZoe MoodieNicole GrunenbergYunda HuangDoug GroveBrittany PrigmoreJia J. KeeDavid BenkeserJohn HuralCraig InnesErica LazarusGraeme MeintjesNivashnee NaickerDishiki KalonjiMaphoshane NchabelengModulakgotla SebeNishanta SinghPhilip KotzeSheetal KassimThozama DubulaVimla NaickerWilliam BrumskineCleon N. NcayiyaAmy M. WardNigel GarrettGirisha KistnasamiZakir GaffoorPearl SelepePhilisiwe B. MakhobaMatsontso P. MathebulaPamela MdaTania AdonisKatlego S. MapetlaBontle ModibediTricia PhilipGladys KobaneCarter BentleyShelly RamirezSimbarashe Takuva, Megan JonesMpho SikhosanaMillicent AtujunaMichele AndrasikNima S. Hejazi, Adrian PurenLubbe WiesnerSanjay PhogatCarlos Diaz GranadosMarguerite KoutsoukosOlivier Van Der Meeren, Susan W. BarnettNiranjan Kanesa-ThasanJames G. KublinM. Juliana McElrathPeter B. GilbertHolly JanesLawrence Corey. (2021) Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults. New England Journal of Medicine 384:12, pages 1089-1100.
Crossref
Jeroen Pollet, Wen-Hsiang Chen & Ulrich Strych. (2021) Recombinant protein vaccines, a proven approach against coronavirus pandemics. Advanced Drug Delivery Reviews 170, pages 71-82.
Crossref
Reza Keikha, Karim Daliri & Ali Jebali. (2021) The Use of Nanobiotechnology in Immunology and Vaccination. Vaccines 9:2, pages 74.
Crossref
Ariel Isaacs, Zheyi Li, Stacey T. M. Cheung, Danushka K. Wijesundara, Christopher L. D. McMillan, Naphak Modhiran, Paul R. Young, Charani Ranasinghe, Daniel Watterson & Keith J. Chappell. (2021) Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines. Vaccines 9:2, pages 71.
Crossref
Manju Nagpal, Malkiet Kaur, Manjinder Singh & Geeta Aggarwal. 2021. Strategies to Overcome Superbug Invasions. Strategies to Overcome Superbug Invasions 227 268 .
Ashish Singla & Sreedevi Upadhyayula. 2020. Handbook of Smart Materials, Technologies, and Devices. Handbook of Smart Materials, Technologies, and Devices 1 49 .
Katlyn Lederer, Diana Castaño, Daniela Gómez Atria, Thomas H. OguinIIIIII, Sidney Wang, Tomaz B. Manzoni, Hiromi Muramatsu, Michael J. Hogan, Fatima Amanat, Patrick Cherubin, Kendall A. Lundgreen, Ying K. Tam, Steven H.Y. Fan, Laurence C. Eisenlohr, Ivan Maillard, Drew Weissman, Paul Bates, Florian Krammer, Gregory D. Sempowski, Norbert Pardi & Michela Locci. (2020) SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity 53:6, pages 1281-1295.e5.
Crossref
Sjoerd T.T. Schetters, R.J. Eveline Li, Laura J.W. Kruijssen, Steef Engels, Martino Ambrosini, Juan J. Garcia-Vallejo, Hakan Kalay, Wendy W.J. Unger & Yvette van Kooyk. (2020) Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity. Biomaterials 262, pages 120342.
Crossref
Jingdi Pan & Zongqiang Cui. (2020) Self‐Assembled Nanoparticles: Exciting Platforms for Vaccination. Biotechnology Journal 15:12.
Crossref
Laura Sánchez de Prada, Iván Sanz Muñoz, Javier Castrodeza Sanz, Raúl Ortiz de Lejarazu Leonardo & José María Eiros Bouza. (2020) Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines. Vaccines 8:4, pages 704.
Crossref
Diksha Gupta, Aishwarya Gangwar, Kiran Jyoti, Vaskuri G.S. Sainaga Jyothi, Rupinder Kaur Sodhi, Neelesh Kumar Mehra, Shashi Bala Singh & Jitender Madan. (2020) Self healing hydrogels: A new paradigm immunoadjuvant for delivering peptide vaccine. Colloids and Surfaces B: Biointerfaces 194, pages 111171.
Crossref
Arthur Sérgio Avelino de Medeiros, Manoela Torres-Rêgo, Ariane Ferreira Lacerda, Hugo Alexandre Oliveira Rocha, Eryvaldo Sócrates Tabosa do Egito, Alianda Maira Cornélio, Denise V. Tambourgi, Matheus de Freitas Fernandes-Pedrosa & Arnóbio Antônio da Silva-Júnior. (2020) Self-Assembled Cationic-Covered Nanoemulsion as A Novel Biocompatible Immunoadjuvant for Antiserum Production Against Tityus serrulatus Scorpion Venom. Pharmaceutics 12:10, pages 927.
Crossref
Mohammad Asaduzzaman Chowdhury, Nayem Hossain, Mohammod Abul Kashem, Md. Abdus Shahid & Ashraful Alam. (2020) Effects of Nanoparticles on Viral Infection — A Review. Nano 15:09, pages 2030003.
Crossref
Sjoerd T. T. Schetters, Laura J. W. Kruijssen, Matheus H. W. Crommentuijn, Hakan Kalay, Joke M. M. Haan & Yvette Kooyk. (2020) Immunological dynamics after subcutaneous immunization with a squalene‐based oil‐in‐water adjuvant. The FASEB Journal 34:9, pages 12406-12418.
Crossref
Tania Gupta & Shishir K Gupta. (2020) Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. International Immunopharmacology 86, pages 106717.
Crossref
Ngee Kiat Chua, Hudson W. Coates & Andrew J. Brown. (2020) Squalene monooxygenase: a journey to the heart of cholesterol synthesis. Progress in Lipid Research 79, pages 101033.
Crossref
Yaoying Wu, Sean H. Kelly, Luis Sanchez-Perez, John H. Sampson & Joel H. Collier. (2020) Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. Biomaterials Science 8:12, pages 3522-3535.
Crossref
Mehdi kheirollahpour, Mohsen Mehrabi, Naser Mohammadpour Dounighi, Mohsen Mohammadi & Alireza Masoudi. (2020) Nanoparticles and Vaccine Development. Pharmaceutical Nanotechnology 8:1, pages 6-21.
Crossref
Adrienne P. Gilkes, Tyler J. Albin, Saikat Manna, Medalyn Supnet, Sara Ruiz, Janine Tom, Alexander J. Badten, Aarti Jain, Rie Nakajima, Jiin Felgner, D. Huw Davies, Samuel A. Stetkevich, Albert Zlotnik, Eric Pearlman, Aysegul Nalca, Philip L. Felgner, Aaron P. Esser-Kahn & Amanda M. Burkhardt. (2020) Tuning Subunit Vaccines with Novel TLR Triagonist Adjuvants to Generate Protective Immune Responses against Coxiella burnetii . The Journal of Immunology 204:3, pages 611-621.
Crossref
Thomas Ebensen, Barbara Fuchs, Kai Schulze & Carlos Alberto Guzmán. 2020. Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids. Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids 285 315 .
Janina M. Jansen, Thomas Gerlach, Husni Elbahesh, Guus F. Rimmelzwaan & Giulietta Saletti. (2019) Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. Journal of Clinical Virology 119, pages 44-52.
Crossref
Pornthep Chanthavanich, Edwin Anderson, Phirangkul Kerdpanich, Michael BulittaNiranjan Kanesa-thasan & Matthew Hohenboken. (2019) Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects. Pediatric Infectious Disease Journal 38:7, pages 757-764.
Crossref
Piotr S. Kowalski, Arnab Rudra, Lei Miao & Daniel G. Anderson. (2019) Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Molecular Therapy 27:4, pages 710-728.
Crossref
Takuya Yamamoto, Yuji Masuta, Masatoshi Momota, Masaru Kanekiyo, Tomohiro Kanuma, Shoukichi Takahama, Eiko Moriishi, Yasuhiro Yasutomi, Takashi Saito, Barney S Graham, Yoshimasa Takahashi & Ken J Ishii. (2019) A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection. International Immunology 31:2, pages 81-90.
Crossref
Sietske K. Rosendahl Huber, Marion Hendriks, Ronald H. J. Jacobi, Jan van de Kassteele, Jolanda C. Mandersloot-Oskam, Renée A. J. van Boxtel, Anne M. J. Wensing, Nynke Y. Rots, Willem Luytjes & Josine van Beek. (2019) Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity. Frontiers in Immunology 9.
Crossref
Thomas Ebensen, Barbara Fuchs, Kai Schulze & Carlos Alberto Guzmán. 2018. Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids. Health Consequences of Microbial Interactions with Hydrocarbons, Oils, and Lipids 1 31 .
Chuan Wang, Pawan Dulal, Xiangyang Zhou, Zhiquan Xiang, Hooman Goharriz, Ashley Banyard, Nicky Green, Livia Brunner, Roland Ventura, Nicolas Collin, Simon J. Draper, Adrian V. S. Hill, Rebecca Ashfield, Anthony R. Fooks, Hildegund C. Ertl & Alexander D. Douglas. (2018) A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. PLOS Neglected Tropical Diseases 12:10, pages e0006870.
Crossref
Sung-Jae Cha, Kyle Jarrod McLean & Marcelo Jacobs-Lorena. (2018) Identification of Plasmodium GAPDH epitopes for generation of antibodies that inhibit malaria infection . Life Science Alliance 1:5, pages e201800111.
Crossref
Rajesh Mani, Manish Gupta, Anshu Malik, Ravi Tandon, Rajendra Prasad, Rakesh Bhatnagar & Nirupama Banerjee. (2018) Adjuvant Potential of Poly-α- l -Glutamine from the Cell Wall of Mycobacterium tuberculosis . Infection and Immunity 86:10.
Crossref
Rushit N. Lodaya, Luis A. Brito, Tom Y.H. Wu, Andrew T. Miller, Gillis R. Otten, Manmohan Singh & Derek T. O'Hagan. (2018) Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators. Journal of Pharmaceutical Sciences 107:9, pages 2310-2314.
Crossref
Xuedan He, Scott I. Abrams & Jonathan F. Lovell. (2018) Peptide Delivery Systems for Cancer Vaccines. Advanced Therapeutics 1:5, pages 1800060.
Crossref
Linda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, Fatima Laher, Georgia D Tomaras, Kristen W Cohen, Mary Allen, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Carter Bentley, Nicole Frahm, Daryl E Morris, Lynn Morris, Nonhlanhla N Mkhize, David C Montefiori, Marcella Sarzotti-Kelsoe, Shannon Grant, Chenchen Yu, Vijay L Mehra, Michael N Pensiero, Sanjay Phogat, Carlos A DiazGranados, Susan W Barnett, Niranjan Kanesa-thasan, Marguerite Koutsoukos, Nelson L Michael, Merlin L Robb, James G Kublin, Peter B Gilbert, Lawrence Corey, Glenda E Gray & M Juliana McElrath. (2018) Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. The Lancet HIV 5:7, pages e366-e378.
Crossref
Yingxia Wen, Hung V. Trinh, Christine E. Linton, Chiara Tani, Nathalie Norais, DeeAnn Martinez-Guzman, Priyanka Ramesh, Yide Sun, Frank Situ, Selen Karaca-Griffin, Christopher Hamlin, Sayali Onkar, Sai Tian, Susan Hilt, Padma Malyala, Rushit Lodaya, Ning Li, Gillis Otten, Giuseppe Palladino, Kristian Friedrich, Yukti Aggarwal, Celia LaBranche, Ryan Duffy, Xiaoying Shen, Georgia D. Tomaras, David C. Montefiori, William Fulp, Raphael Gottardo, Brian Burke, Jeffrey B. Ulmer, Susan Zolla-Pazner, Hua-Xin Liao, Barton F. Haynes, Nelson L. Michael, Jerome H. Kim, Mangala Rao, Robert J. O’Connell, Andrea Carfi & Susan W. Barnett. (2018) Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. PLOS ONE 13:4, pages e0194266.
Crossref
Rachel F. MaderaLihua WangWenjie GongYulia BurakovaSterling BuistJerome NietfeldJamie HenningsonAda G. Cino-OzunaChangchun TuJishu Shi. (2018) Toward the development of a one-dose classical swine fever subunit vaccine: antigen titration, immunity onset, and duration of immunity. Journal of Veterinary Science 19:3, pages 393.
Crossref
Behiye Şenel & Gülay Büyükköroğlu. 2018. Multifunctional Nanocarriers for Contemporary Healthcare Applications. Multifunctional Nanocarriers for Contemporary Healthcare Applications 381 414 .
T. Lorenz, S. Bojko, H. Bunjes & A. Dietzel. (2018) An inert 3D emulsification device for individual precipitation and concentration of amorphous drug nanoparticles. Lab on a Chip 18:4, pages 627-638.
Crossref
Reshma J. Nevagi, Istvan Toth & Mariusz Skwarczynski. 2018. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Peptide Applications in Biomedicine, Biotechnology and Bioengineering 327 358 .
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Claire-Anne Siegrist & Andrew J. Pollard. (2017) AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Frontiers in Immunology 8.
Crossref
Jean-Marc Cavaillon & Mervyn SingerDennis M. Klinman & Hidekazu Shirota. 2017. Inflammation - From Molecular and Cellular Mechanisms to the Clinic. Inflammation - From Molecular and Cellular Mechanisms to the Clinic 143 174 .
Bin Li, Hanmei Yuan, Li Chen, Heqiang Sun, Jian Hu, Shanshan Wei, Zhuo Zhao, Quanming Zou & Chao Wu. (2017) The influence of adjuvant on UreB protection against Helicobacter pylori through the diversity of CD4+ T-cell epitope repertoire . Oncotarget 8:40, pages 68138-68152.
Crossref
Neal Van Hoeven, Christopher B. Fox, Brian Granger, Tara Evers, Sharvari W. Joshi, Ghislain I. Nana, Sarah C. Evans, Susan Lin, Hong Liang, Li Liang, Rie Nakajima, Philip L. Felgner, Richard A. Bowen, Nicole Marlenee, Airn Hartwig, Susan L. Baldwin, Rhea N. Coler, Mark Tomai, James Elvecrog, Steven G. Reed & Darrick Carter. (2017) A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines. Scientific Reports 7:1.
Crossref
Jean Cornier, Andrew Owen, Arno Kwade & Marcel Van de Voorde. 2017. Pharmaceutical Nanotechnology: Innovation and Production. Pharmaceutical Nanotechnology: Innovation and Production 175 230 .
K.L. Wilson, S.D. Xiang & M. Plebanski. 2017. Micro and Nanotechnology in Vaccine Development. Micro and Nanotechnology in Vaccine Development 99 125 .
Robert A. Mitchell, Rita Altszuler, Ute Frevert & Elizabeth H. Nardin. (2016) Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity. Scientific Reports 6:1.
Crossref
Jessica A. Hess, Bin Zhan, April R. Torigian, John B. Patton, Nikolai Petrovsky, Tingting Zhan, Maria Elena Bottazzi, Peter J. Hotez, Thomas R. Klei, Sara Lustigman & David Abraham. (2016) The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLOS Neglected Tropical Diseases 10:7, pages e0004797.
Crossref
Kimia Kardani, Azam Bolhassani & Sepideh Shahbazi. (2016) Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. Vaccine 34:4, pages 413-423.
Crossref
Matthias GieseMatthias Giese. 2016. Introduction to Molecular Vaccinology. Introduction to Molecular Vaccinology 145 163 .
Paolo Pellegrino, Emilio Clementi & Sonia Radice. (2015) On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives. Autoimmunity Reviews 14:10, pages 880-888.
Crossref
Raúl Ortiz de Lejarazu & Sonia Tamames. (2015) Vacunación antigripal. Efectividad de las vacunas actuales y retos de futuro. Enfermedades Infecciosas y Microbiología Clínica 33:7, pages 480-490.
Crossref
Casey Johnson, Matthew Hohenboken, Terry Poling, Peter Jaehnig & Niranjan Kanesa-thasan. (2015) Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study. The Journal of Infectious Diseases 212:1, pages 72-80.
Crossref
D. L. F. Portuondo, L. S. Ferreira, A. C. Urbaczek, A. Batista-Duharte & I. Z. Carlos. (2014) Adjuvants and delivery systems for antifungal vaccines: Current state and future developments. Medical Mycology 53:1, pages 69-89.
Crossref
Markus Knuf, Geert Leroux-Roels, Hans. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Arora, Dorothee Kieninger-Baum & Giovanni Della Cioppa. (2015) Safety and immunogenicity of an MF59®-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine 33:1, pages 174-181.
Crossref
Ruchi R. Shah, Luis A. Brito, Derek T. O’Hagan & Mansoor M. Amiji. 2015. Subunit Vaccine Delivery. Subunit Vaccine Delivery 59 76 .
Barbara Camilloni, Michela Basileo, Angela Di Martino, Isabella Donatelli & Anna Maria Iorio. (2014) Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A(H3N2) strains. Immunity & Ageing 11:1.
Crossref
Robert B Couch, José M Bayas, Covadonga Caso, Innocent Nnadi Mbawuike, Concepción Núñez López, Carine Claeys, Mohamed El Idrissi, Caroline Hervé, Béatrice Laupèze, Lidia Oostvogels & Philippe Moris. (2014) Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infectious Diseases 14:1.
Crossref
Markus Knuf, Geert Leroux-Roels, Hans. C. Rümke, Katia Abarca, Luis Rivera, Maria Lattanzi, Paola Pedotti, Ashwani Arora, Dorothee Kieninger-Baum & Giovanni Della Cioppa. (2014) Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age. Pediatric Infectious Disease Journal 33:12, pages e320-e329.
Crossref
Chen Wang, Xiaokang Li, Tingcai Wu, Deyuan Li, Mingfu Niu, Yang Wang, Chunjie Zhang, Xiangchao Cheng & Puyan Chen. (2014) Bursin-like peptide (BLP) enhances H9N2 influenza vaccine induced humoral and cell mediated immune responses. Cellular Immunology 292:1-2, pages 57-64.
Crossref
Terry Nolan, Lulu Bravo, Ana Ceballos, Essack Mitha, Glenda Gray, Beatriz Quiambao, Sanjay S. Patel, Svetlana Bizjajeva, Hans Bock, Nancy Nazaire-Bermal, Eduardo Forleo-Neto, Giovanni Della Cioppa & Vas Narasimhan. (2014) Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children. Vaccine 32:46, pages 6146-6156.
Crossref
Mi-Gyeong Kim, Joo Yeon Park, Yuna Shon, Gunwoo Kim, Gayong Shim & Yu-Kyoung Oh. (2014) Nanotechnology and vaccine development. Asian Journal of Pharmaceutical Sciences 9:5, pages 227-235.
Crossref
Barbara C. Gärtner & Tim Meyer. (2014) Vaccination in Elite Athletes. Sports Medicine 44:10, pages 1361-1376.
Crossref
Tuen-Ching Chan, Ivan Fan-Ngai Hung, Kwok-Hung Chan, Clara Pui-Yan Li, Patrick Tsz-Wai Li, James Ka-Hay Luk, Leung-Wing Chu & Felix Hon-Wai Chan. (2014) Immunogenicity and Safety of Intradermal Trivalent Influenza Vaccination in Nursing Home Older Adults: A Randomized Controlled Trial. Journal of the American Medical Directors Association 15:8, pages 607.e5-607.e12.
Crossref
Chia-Ying Wu, Ching-Yuan Chang, Hsiu-Hua Ma, Chiung-Wen Wang, Yung-Tsung Chen, Pei-Wen Hsiao, Ching-Chuan Chang, Chi-Hsien Chan, Chung-Cheng Liu & Juine-Ruey Chen. (2014) Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine 32:35, pages 4485-4494.
Crossref
Susanna Esposito, Paolo Durando, Samantha Bosis, Filippo Ansaldi, Claudia Tagliabue & Giancarlo Icardi. (2014) Vaccine-preventable diseases: From paediatric to adult targets. European Journal of Internal Medicine 25:3, pages 203-212.
Crossref
Richard D Antrobus, Tamara K Berthoud, Caitlin E Mullarkey, Katja Hoschler, Lynda Coughlan, Maria Zambon, Adrian VS Hill & Sarah C Gilbert. (2014) Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses. Molecular Therapy 22:1, pages 233-238.
Crossref
Liang Zhao, Arjun Seth, Nani Wibowo, Chun-Xia Zhao, Neena Mitter, Chengzhong Yu & Anton P.J. Middelberg. (2014) Nanoparticle vaccines. Vaccine 32:3, pages 327-337.
Crossref
Michela Basileo, Anna Maria Iorio, Guido Bartolini, Cinzia Bianchini, Giuseppe Menculini, Paolo Tozzi & Barbara Camilloni. (2014) Comparative Study of Immunogenicity of Split, Intradermal and MF59-adjuvanted Influenza Vaccines in Elderly Institutionalized Subjects. Procedia in Vaccinology 8, pages 18-23.
Crossref
Jesús Arenas. 2014. Molecular Vaccines. Molecular Vaccines 527 536 .
Hans C Rümke, Jan Hendrik Richardus, Lars Rombo, Karlis Pauksens, Georg Plaßmann, Christelle Durand, Jeanne-Marie Devaster, Walthère Dewé & Lidia Oostvogels. (2013) Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infectious Diseases 13:1.
Crossref
Rajesh K. Gupta. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 32 .
P. Wutzler & M. Knuf. (2013) Influenza und Influenzaimpfstoffe für KinderInfluenza and influenza vaccines for children. Monatsschrift Kinderheilkunde 161:8, pages 749-760.
Crossref
Samuele Calabro, Elaine Tritto, Annamaria Pezzotti, Marianna Taccone, Alessandro Muzzi, Sylvie Bertholet, Ennio De Gregorio, Derek T. O’Hagan, Barbara Baudner & Anja Seubert. (2013) The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31:33, pages 3363-3369.
Crossref
Luis A. Brito, Padma Malyala & Derek T. O’Hagan. (2013) Vaccine adjuvant formulations: A pharmaceutical perspective. Seminars in Immunology 25:2, pages 130-145.
Crossref
Roland Ventura, Livia Brunner, Bambang Heriyanto, Otto de Boer, Michael O’Hara, Chuong Huynh, Mahendra Suhardono & Nicolas Collin. (2013) Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. Vaccine 31:12, pages 1641-1645.
Crossref
Darren R. Flower. 2013. Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines. Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines 155 180 .
Julia Elizabeth Mainwaring Upton, David Brian Hummel, Anna Kasprzak & Adelle Roberta Atkinson. (2012) No systemic reactions to influenza vaccination in egg-sensitized tertiary-care pediatric patients. Allergy, Asthma & Clinical Immunology 8:1.
Crossref
Xavier Duval, Adrian Caplanusi, Henri Laurichesse, Dominique Deplanque, Pierre Loulergue, Tejaswini Vaman, Odile Launay & Paul Gillard. (2012) Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial. BMC Infectious Diseases 12:1.
Crossref
Marie‐Françoise Klucker, François Dalençon, Patricia Probeck & Jean Haensler. (2012) AF03, An Alternative Squalene Emulsion‐Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature Method. Journal of Pharmaceutical Sciences 101:12, pages 4490-4500.
Crossref
Fiona A. Sharp & Ed C. Lavelle. 2012. Vaccinology. Vaccinology 361 374 .
Derek T. O'Hagan & Andreas Wack. 2012. Vaccinology. Vaccinology 348 360 .
Christine M Oshansky & Paul G Thomas. (2012) The human side of influenza. Journal of Leukocyte Biology 92:1, pages 83-96.
Crossref
Christoph Hatz, Jakob P. Cramer, André Vertruyen, Tino F. Schwarz, Frank von Sonnenburg, Astrid Borkowski, Maria Lattanzi, Anne Katrin Hilbert, Giovanni Della Cioppa & Geert Leroux-Roels. (2012) A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations. Vaccine 30:32, pages 4820-4827.
Crossref
D.T. O’Hagan, G.S. Ott, E. De Gregorio & A. Seubert. (2012) The mechanism of action of MF59 – An innately attractive adjuvant formulation. Vaccine 30:29, pages 4341-4348.
Crossref
Christoph Hatz, Frank von Sonnenburg, Daniela Casula, Maria Lattanzi & Geert Leroux-Roels. (2012) A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 30:23, pages 3470-3477.
Crossref
Gerhard Winter & Julia Myschik. 2012. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology 235 256 .
Rachel P. J. Lai, Michael S. Seaman, Paul Tonks, Frank Wegmann, David J. Seilly, Simon D. W. Frost, Celia C. LaBranche, David C. Montefiori, Antu K. Dey, Indresh K. Srivastava, Quentin Sattentau, Susan W. Barnett & Jonathan L. Heeney. (2012) Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants. PLoS ONE 7:4, pages e35083.
Crossref
Cynthia Nassim, Shane Christensen, Dan Henry, Sandra Holmes, Matthew Hohenboken & Niranjan Kanesa-Thasan. (2012) Identification of Antigen and Adjuvant Doses Resulting in Optimal Immunogenicity and Antibody Persistence up to 1 Year After Immunization With a Pandemic A/H1N1 Influenza Vaccine in Children 3 to <9 Years of Age. Pediatric Infectious Disease Journal 31:4, pages e59-e65.
Crossref
Antu K. Dey, Brian Burke, Yide Sun, Karin Hartog, Jonathan L. Heeney, David Montefiori, Indresh K. Srivastava & Susan W. Barnett. (2012) Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. Vaccine 30:17, pages 2749-2759.
Crossref
J. Ruiz-Aragón, J.M. Molina Linde, R. Yang, S. Márquez-Peláez, P. Moya Cordero & R. Rodríguez López. (2012) Seguridad de la vacuna antigripal con el adyuvante MF59. Revisión sistemática de la literatura. Vacunas 13:2, pages 49-56.
Crossref
Penghui Yang, Yueqiang Duan, Peirui Zhang, Zhiwei Li, Cheng Wang, Mei Dong, Chong Tang, Li Xing, Hongjing Gu, Zhongpeng Zhao, Xiufan Liu, Shaogeng Zhang & Xiliang Wang. (2012) Multiple-Clade H5N1 Influenza Split Vaccine Elicits Broad Cross Protection against Lethal Influenza Virus Challenge in Mice by Intranasal Vaccination. PLoS ONE 7:1, pages e30252.
Crossref
Se-Min Hwang, Hack-Lyoung Kim, Kyueng-Whan Min, Min Kim, Jae-Sung Lim, Jin-Man Choi, Byung-Chul Chun, Min-Jeong Kim, Sang-Min Lee, Seung-Young Kim & Han-Ho Jeon. (2012) Comparison of the Adverse Events Associated with MF59-Adjuvanted and Non-Adjuvanted H1N1 Vaccines in Healthy Young Male Korean Soldiers. Japanese Journal of Infectious Diseases 65:3, pages 193-197.
Crossref
Anna Smed-Sörensen & Karin Loré. 2013. HIV Interactions with Dendritic Cells. HIV Interactions with Dendritic Cells 263 288 .
Vesna Milacic, Brittany Agius Bailey, Derek O’Hagan & Steven P. Schwendeman. 2012. Long Acting Injections and Implants. Long Acting Injections and Implants 429 458 .
Fiona A. Sharp & Ed C. Lavelle. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 14 .
Timo Vesikari, Markus Knuf, Peter Wutzler, Aino Karvonen, Dorothee Kieninger-Baum, Heinz-Josef Schmitt, Frank Baehner, Astrid Borkowski, Theodore F. Tsai & Ralf Clemens. (2011) Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children. New England Journal of Medicine 365:15, pages 1406-1416.
Crossref
Susanna Esposito & Nicola Principi. (2011) Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. Vaccine 29:43, pages 7535-7541.
Crossref
John Steel. (2012) New Strategies for the Development of H5N1 Subtype Influenza Vaccines. BioDrugs 25:5, pages 285-298.
Crossref
Fabio BagnoliBarbara BaudnerRavi P.N. MishraErika BartoliniLuigi FiaschiPaolo MariottiVincenzo Nardi-DeiPhil BoucherRino Rappuoli. (2011) Designing the Next Generation of Vaccines for Global Public Health. OMICS: A Journal of Integrative Biology 15:9, pages 545-566.
Crossref
Luis A. Brito, Michelle Chan, Barbara Baudner, Simona Gallorini, George Santos, Derek T. O’Hagan & Manmohan Singh. (2011) An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 29:37, pages 6262-6268.
Crossref
Ida Rosenkrands, Carina Vingsbo-Lundberg, Trine Junker Bundgaard, Thomas Lindenstrøm, Vincent Enouf, Sylvie van der Werf, Peter Andersen & Else Marie Agger. (2011) Enhanced humoral and cell-mediated immune responses after immunization with trivalent influenza vaccine adjuvanted with cationic liposomes. Vaccine 29:37, pages 6283-6291.
Crossref
Wei Wang & Manmohan Singh. 2011. Development of Vaccines. Development of Vaccines 327 383 .
Valentina Parodi, Daniela de Florentiis, Mariano Martini & Filippo Ansaldi. (2011) Inactivated Influenza Vaccines. Drugs & Aging 28:2, pages 93-106.
Crossref
Wei Wang & Manmohan Singh. (2011) Selection of Adjuvants for Enhanced Vaccine Potency. World Journal of Vaccines 01:02, pages 33-78.
Crossref
Philip R. Dormitzer, Grazia Galli, Flora Castellino, Hana Golding, Surender Khurana, Giuseppe Del Giudice & Rino Rappuoli. (2011) Influenza vaccine immunology. Immunological Reviews 239:1, pages 167-177.
Crossref
Pierre Van Damme, Robert Arnou, Froukje Kafeja, Anne Fiquet, Patrick Richard, Stéphane Thomas, Gilles Meghlaoui, Sandrine Isabelle Samson & Emilio Ledesma. (2010) Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infectious Diseases 10:1.
Crossref
Jiri Beran, Ibrahim A. Abdel-Messih, Jolana Raupachova, Lenka Hobzova & Elena Fragapane. (2010) A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clinical Therapeutics 32:13, pages 2186-2197.
Crossref
Timo VesikariAino KarvonenSandrine TilmanAstrid Borkowski, Emanuele Montomoli, Angelika BanzhoffRalf Clemens. (2010) Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence. Pediatrics 126:4, pages e762-e770.
Crossref
J.R. De Juanes Pardo, M.P. Arrazola Martínez & A. García de Codes Ilario. (2010) Vacunación frente a la gripe por vía intradérmica. Vacunas 11:4, pages 143-145.
Crossref
I. Tamayo, J. M. Irache, C. Mansilla, J. Ochoa-Repáraz, J. J. Lasarte & C. Gamazo. (2010) Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation. Clinical and Vaccine Immunology 17:9, pages 1356-1362.
Crossref
Yuji Yasuda, Ryoya Komatsu, Kenji Matsushita, Taketsugu Minami, Yutaka Suehiro, Hiroshi Sawata, Noriko Nakura, Ralf K. Jaeger & Maria Lattanzi. (2010) Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Advances in Therapy 27:7, pages 444-457.
Crossref
Ali M. Harandi, Donata Medaglini & Robin J. Shattock. (2010) Vaccine adjuvants: A priority for vaccine research. Vaccine 28:12, pages 2363-2366.
Crossref
Donatella Pietrella, Anna Rachini, Antonella Torosantucci, Paola Chiani, Alistair J.P. Brown, Francesco Bistoni, Paolo Costantino, Paolo Mosci, Christophe d’Enfert, Rino Rappuoli, Antonio Cassone & Anna Vecchiarelli. (2010) A β-glucan-conjugate vaccine and anti-β-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 28:7, pages 1717-1725.
Crossref
Neil C Robson, Sabine Hoves, Eugene Maraskovsky & Max Schnurr. (2010) Presentation of tumour antigens by dendritic cells and challenges faced. Current Opinion in Immunology 22:1, pages 137-144.
Crossref
Wendy Keitel, Nicola Groth, Maria Lattanzi, Michaela Praus, Anne Katrin Hilbert, Astrid Borkowski & Ted F. Tsai. (2010) Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 28:3, pages 840-848.
Crossref
Richard Brunner, Erika Jensen-Jarolim & Isabella Pali-Schöll. (2010) The ABC of clinical and experimental adjuvants—A brief overview. Immunology Letters 128:1, pages 29-35.
Crossref
S. Otero Romero & F.A. Moraga Llop. (2010) Desarrollo y autorización de vacunas pandémicas de la gripe A (H1N1) 2009. Vacunas 11:1, pages 17-24.
Crossref
T. Ebensen, B. Fuchs, K. Schulze & C. A. Guzmán. 2010. Handbook of Hydrocarbon and Lipid Microbiology. Handbook of Hydrocarbon and Lipid Microbiology 3311 3331 .
L. Harivardhan Reddy & Patrick Couvreur. (2009) Squalene: A natural triterpene for use in disease management and therapy. Advanced Drug Delivery Reviews 61:15, pages 1412-1426.
Crossref
Shubham Shrivastava, Kavita S. Lole, Anuradha S. Tripathy, Umesh S. Shaligram & Vidya A. Arankalle. (2009) Development of candidate combination vaccine for hepatitis E and hepatitis B: A liposome encapsulation approach. Vaccine 27:47, pages 6582-6588.
Crossref
S.H.E. Kaufmann, A.L. Meinke & A. von Gabain. (2009) Neue Impfstoffkonzepte auf Basis moderner Erkenntnisse der ImmunologieNovel vaccination concepts on the basis of modern insights into immunology. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 52:11, pages 1069-1082.
Crossref
T. Vesikari, N. Groth, A. Karvonen, A. Borkowski & M. Pellegrini. (2009) MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:45, pages 6291-6295.
Crossref
Nilton Lincopan, Noelí M. Espíndola, Adelaide J. Vaz, Maria Helena B. da Costa, Eliana Faquim-Mauro & Ana M. Carmona-Ribeiro. (2009) Novel immunoadjuvants based on cationic lipid: Preparation, characterization and activity in vivo. Vaccine 27:42, pages 5760-5771.
Crossref
Joan Puig-Barberà. (2009) MF59 ® -adjuvanted seasonalinfluenza vaccine . Aging Health 5:4, pages 475-481.
Crossref
Arnold S. Monto, Filippo Ansaldi, Richard Aspinall, Janet E. McElhaney, Luis F. Montaño, Kristin L. Nichol, Joan Puig-Barberà, Joe Schmitt & Iain Stephenson. (2009) Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 27:37, pages 5043-5053.
Crossref
Timo Vesikari, Michele Pellegrini, Aino Karvonen, Nicola Groth, Astrid Borkowski, Derek T. O'Hagan & Audino Podda. (2009) Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. Pediatric Infectious Disease Journal 28:7, pages 563-571.
Crossref
Eugene Maraskovsky, Max Schnurr, Nick S Wilson, Neil C Robson, Jeff Boyle & Debbie Drane. (2009) Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant. Immunology & Cell Biology 87:5, pages 371-376.
Crossref
Heather L. Forrest, Alexey M. Khalenkov, Elena A. Govorkova, Jeong-Ki Kim, Giuseppe Del Giudice & Robert G. Webster. (2009) Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27:31, pages 4187-4195.
Crossref
Velio Bocci, Valter Travagli & Iacopo Zanardi. (2009) The failure of HIV vaccines: A new autovaccine may overcome some problems. Medical Hypotheses 72:6, pages 662-664.
Crossref

Displaying 200 of 215 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.